Sugi Predict

Sugi Predict / Targets / DHODH

DHODH

Dihydroorotate dehydrogenase (quinone), mitochondrial · Q02127 · DHODH on Sugi Atlas →

158,282 patent compounds predicted against DHODH, 74,236 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Brequinar Brequinar (SCHEMBL4265) 1.00 20/20
Brequinar Brequinar (SCHEMBL49400) 1.00 19/20
Brequinar Brequinar (SCHEMBL4266) 0.98 19/20
SCHEMBL51142 SCHEMBL51142 0.51 18/20
SCHEMBL51143 SCHEMBL51143 0.51 18/20
SCHEMBL51144 SCHEMBL51144 0.51 18/20
SCHEMBL39712 SCHEMBL39712 0.44 17/20
SCHEMBL207547 SCHEMBL207547 0.52 15/20
SCHEMBL44527 SCHEMBL44527 0.37 13/20
Water Water (SCHEMBL147605) 0.36 13/20
SCHEMBL206045 SCHEMBL206045 0.61 12/20
SCHEMBL206039 SCHEMBL206039 0.59 12/20
SCHEMBL116029 SCHEMBL116029 0.74 11/20
SCHEMBL39083 SCHEMBL39083 0.61 11/20
SCHEMBL206784 SCHEMBL206784 0.51 10/20
Teriflunomide Teriflunomide (SCHEMBL22661) 1.00 9/20
SCHEMBL116042 SCHEMBL116042 0.94 9/20
SCHEMBL117357 SCHEMBL117357 0.71 9/20
Flunixin Flunixin (SCHEMBL42911) 1.00 8/20
SCHEMBL42477 SCHEMBL42477 0.81 8/20

Clinical trials — most relevant to DHODH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment PHASE4RECRUITING
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease PHASE3COMPLETED
Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis PHASE3COMPLETED
A Study of PTC923 in Participants With Phenylketonuria PHASE3COMPLETED
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer PHASE2/PHASE3RECRUITING
Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum PHASE3COMPLETED
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria PHASE3ACTIVE_NOT_RECRUITING
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer PHASE2UNKNOWN
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene PHASE2COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer PHASE2UNKNOWN
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer PHASE2UNKNOWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer PHASE1RECRUITING
Mechanistic Studies of Teriflunomide in RRMS nanCOMPLETED
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings nanNOT_YET_RECRUITING
Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis nanRECRUITING
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii nanACTIVE_NOT_RECRUITING
SPK Study in Afghanistan nanCOMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. nanCOMPLETED
Antimalarial Drug Resistance in Mali nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization nanCOMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer nanUNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients nanRECRUITING
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer nanCOMPLETED
TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study nanCOMPLETED
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DHODH binder may also engage these)

ProteinNameSimilarity
O35435 — 1.000 O35435 →
Q5R6X6 — 1.000 Q5R6X6 →
Q5E9W3 — 1.000 Q5E9W3 →
Q63707 — 1.000 Q63707 →
Q4UTX5 — 0.993 Q4UTX5 →
Q7XKC8 — 0.993 Q7XKC8 →
Q9FB59 — 0.992 Q9FB59 →
A9CK85 — 0.992 A9CK85 →
B3PIL8 — 0.991 B3PIL8 →
P32748 — 0.989 P32748 →
Q8D9G5 — 0.988 Q8D9G5 →
Q2KW44 — 0.988 Q2KW44 →
P12928 — 0.987 P12928 →
A5VNQ1 — 0.987 A5VNQ1 →
Q6V3W9 — 0.987 Q6V3W9 →
B3R4T0 — 0.987 B3R4T0 →
Q8YFB1 — 0.987 Q8YFB1 →
A9M7Z9 — 0.987 A9M7Z9 →
B0CJU0 — 0.987 B0CJU0 →
B7LNV5 — 0.987 B7LNV5 →
B5F1U2 — 0.986 B5F1U2 →
B5FQY8 — 0.986 B5FQY8 →
Q39GX5 — 0.986 Q39GX5 →
Q3KFC7 — 0.986 Q3KFC7 →
A3NUS1 — 0.986 A3NUS1 →
Q63TV1 — 0.986 Q63TV1 →
Q89VA7 — 0.986 Q89VA7 →
A4XWQ0 — 0.986 A4XWQ0 →
Q02PL5 — 0.986 Q02PL5 →
A7HQ77 — 0.986 A7HQ77 →